Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 Treatment Algorithm for PAH Adapted From 2007 ACCP Guidelines
Letters following recommendations are based on a combination of level of evidence and perceived benefit: A = strong recommendation; B = moderate recommendation; C = weak recommendation. Recommendations with an E are based on expert opinion rather than clinical trial evidence. Ambrisentan was approved for functional class II and III pulmonary arterial hypertension (PAH) after these guidelines were published. ACCP = American College of Chest Physicians; CCB = calcium-channel blocker; FC = functional class; INH = inhaled; IPAH = idiopathic pulmonary arterial hypertension; IV = intravenous; SC = subcutaneous. Reproduced, with permission, from Badesch et al. (49).
|
